Skip to main
  1. Stocks
  2. Arvinas Inc
  3. Forecast
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Arvinas is positioned for a meaningful catalyst cycle in 3Q26-2027, with initial ARV-393 monotherapy data expected in 4Q26, a broader update in mid-2027, and additional readouts for ARV-027, ARV-6723, and ARV-102 that could validate its protein-degradation platform across oncology and neurology. The core bullish case is that early clinical evidence could move the story from platform promise to measurable efficacy, especially if ARV-393 shows response rates above 30% in its early T-cell lymphoma cohort, along with supportive safety, PK/PD, and BCL6 degradation signals. While the outlook also reflects a lower $13 valuation versus $18 due to revised launch and regulatory assumptions, the company’s broad pipeline, seven checkpoint-resistant preclinical models, and European-led path for ARV-102 support long-term optionality and make weakness in the shares potentially attractive.

Bears say

Arvinas is facing a weaker fundamental outlook because management has had to reassess launch assumptions across its pipeline, pushing expected cash flows farther into the future and lowering their present value. The decision to seek an out-licensing agreement for additional ARV-806 trials signals capital constraints and a need to reprioritize a program that would require substantial funding to stay competitive, while early monotherapy dose-escalation data remained immature on clinical activity and tolerability. On top of these execution risks, the company still faces meaningful clinical, regulatory, competitive, and financing risk, including the possibility of additional equity financing to support development.

Arvinas Inc (ARVN) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Arvinas Inc (ARVN) Analyst Forecast & Price Prediction

Get the latest Arvinas Inc (ARVN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arvinas Inc (ARVN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 9 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Arvinas Inc (ARVN) Analyst Forecast & Price Prediction

Get the latest Arvinas Inc (ARVN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arvinas Inc (ARVN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ARVN stock data and trends